At the last annual meeting of the European Society of Nuclear Medicine 2016, prostate-specific membrane antigen (PSMA) imaging for prostate cancer (PCA) and somatostatin receptor imaging for neuroendocrine tumors (NET) attracted the most attention in their early clinical results and linkage to radionuclide therapy. This evidence concerns the gene FOLH1 and neuroendocrine neoplasm.